Biologics In The Spotlight: Novartis' Canakinumab
You may also be interested in...
Novartis showed off its new drug pipeline for the first time in three years Nov. 19, but the R&D day was as much about vindicating the novel research strategy it rolled out in 2002 as it was previewing the work in process.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials